NDA Day: FDA is planning an NDA day "later this month" to wrap up the review of one late-stage application. Center for Drug Evaluation and Research Deputy Director Gerald Meyer notes that "NDA day" reviews take about one month to complete versus three to five months for second and third level reviews on an average NDA at FDA.
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.